BLA

(redirected from biologics license application)
Also found in: Medical.
Related to biologics license application: New drug application

BLA

abbr.
Bachelor of Liberal Arts
References in periodicals archive ?
Blood supply organisation The Community Blood Center (CBC) reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for the distribution of platelets that have been pathogen-reduced with the INTERCEPT Blood System.
NORDIC BUSINESS REPORT-August 15, 2014-Pfizer reports US FDA's acceptance of Biologics License Application and Priority Review designation for meningococcal B vaccine candidate
UCB has received a Complete Response Letter from the United States Food and Drug Administration (FDA) requesting additional information and clarification on data submitted in its Biologics License Application (BLA) for the approval of CIMZIATM in Crohn's disease.
OMRIX" or the "Company") (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today that it has submitted a Biologics License Application (BLA) to the U.
M2 EQUITYBITES-January 17, 2018-US FDA accepts for review Pharming Group's supplemental Biologics License Application for RUCONEST
M2 PHARMA-January 17, 2018-US FDA accepts for review Pharming Group's supplemental Biologics License Application for RUCONEST
A Biologics License Application is expected to be filed with the FDA in late 2005.
M2 EQUITYBITES-January 16, 2018-US FDA accepts Sandoz's Biologics License Application for proposed biosimilar adalimumab
M2 PHARMA-November 28, 2017-Pharming Group submits US supplemental biologics license application for Ruconest
Upon FDA approval of the biologics license application (BLA) for Omr-IgG-am in the United States, FFF will become the product's exclusive authorized distributor for five years.
M2 EQUITYBITES-November 28, 2017-Pharming Group submits US supplemental biologics license application for Ruconest
M2 PHARMA-July 19, 2017-US Food and Drug Administration rejects Amgen and UCB's biologics license application for Evenity

Full browser ?